133 related articles for article (PubMed ID: 37674951)
1. The Demographic and Clinicopathological Characteristics of Hepatopancreatobiliary Cancers From a Specialized Center in India.
Sahai P; Yadav HP; Rastogi A
Cureus; 2023 Aug; 15(8):e43026. PubMed ID: 37674951
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.
Dyson J; Jaques B; Chattopadyhay D; Lochan R; Graham J; Das D; Aslam T; Patanwala I; Gaggar S; Cole M; Sumpter K; Stewart S; Rose J; Hudson M; Manas D; Reeves HL
J Hepatol; 2014 Jan; 60(1):110-7. PubMed ID: 23978719
[TBL] [Abstract][Full Text] [Related]
3. Geographical and Temporal Variation in the Incidence and Mortality of Hepato-Pancreato-Biliary Primary Malignancies:1990-2017.
Weaver AJ; Stafford R; Hale J; Denning D; Sanabria JR;
J Surg Res; 2020 Jan; 245():89-98. PubMed ID: 31404895
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.
Lin BZ; Lin TJ; Lin CL; Liao LY; Chang TA; Lu BJ; Chen KY
J Chin Med Assoc; 2021 Jun; 84(6):606-613. PubMed ID: 33871391
[TBL] [Abstract][Full Text] [Related]
5. Incidence and survival for hepatic, pancreatic and biliary cancers in England between 1998 and 2007.
Coupland VH; Kocher HM; Berry DP; Allum W; Linklater KM; Konfortion J; Møller H; Davies EA
Cancer Epidemiol; 2012 Aug; 36(4):e207-14. PubMed ID: 22534487
[TBL] [Abstract][Full Text] [Related]
6. Experience With Changing Etiology and Nontransplant Curative Treatment Modalities for Hepatocellular Carcinoma in a Real-Life Setting-A Retrospective Descriptive Analysis.
Tohra S; Duseja A; Taneja S; Kalra N; Gorsi U; Behera A; Kaman L; Dahiya D; Sahu S; Sharma B; Singh V; Dhiman RK; Chawla Y
J Clin Exp Hepatol; 2021; 11(6):682-690. PubMed ID: 34866847
[TBL] [Abstract][Full Text] [Related]
7. Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme.
Hassan I; Gane E
Intern Med J; 2019 Nov; 49(11):1405-1411. PubMed ID: 30908822
[TBL] [Abstract][Full Text] [Related]
8. Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma.
Hester CA; Rich NE; Singal AG; Yopp AC
J Natl Compr Canc Netw; 2019 Apr; 17(4):322-329. PubMed ID: 30959469
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).
Paik JM; Eberly KE; Kabbara K; Harring M; Younossi Y; Henry L; Verma M; Younossi ZM
Ann Hepatol; 2023; 28(4):101108. PubMed ID: 37088421
[TBL] [Abstract][Full Text] [Related]
10. Role of genetic testing in hepatic, pancreatic, and biliary cancers.
Hewitt DB; Aziz H; Brown ZJ; Pawlik TM
Surg Oncol; 2022 Sep; 44():101844. PubMed ID: 36116416
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Thomas JA; Kendall BJ; Dalais C; Macdonald GA; Thrift AP
Eur J Cancer; 2022 Sep; 173():250-262. PubMed ID: 35944373
[TBL] [Abstract][Full Text] [Related]
12. Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection.
Wu HC; Jeng WJ; Pan MH; Hsieh YC; Lu SN; Chen CJ; Yang HI
JHEP Rep; 2022 Feb; 4(2):100410. PubMed ID: 35079699
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of HPB malignancy in the elderly.
Pericleous M; Khan SA
Eur J Surg Oncol; 2021 Mar; 47(3 Pt A):503-513. PubMed ID: 32360064
[TBL] [Abstract][Full Text] [Related]
14. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics analysis of 1180 patients with hepatocellular carcinoma secondary to hepatitis B, hepatitis C and alcoholic liver disease.
Zhao H; Zhu P; Han T; Ye Q; Xu C; Wu L; Liu F; Yin W; Li Z; Guo Y
J Clin Lab Anal; 2020 Feb; 34(2):e23075. PubMed ID: 31659795
[TBL] [Abstract][Full Text] [Related]
16. Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies.
Elshami M; Ahmed FA; Hue JJ; Kakish H; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
Surgery; 2023 Feb; 173(2):289-298. PubMed ID: 36402613
[TBL] [Abstract][Full Text] [Related]
17. Hepatopancreatobiliary malignancies: time to treatment matters.
Kerekes DM; Frey AE; Bakkila BF; Johnson CH; Becher RD; Billingsley KG; Khan SA
J Gastrointest Oncol; 2023 Apr; 14(2):833-848. PubMed ID: 37201090
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States.
Younossi ZM; Stepanova M; Ong J; Trimble G; AlQahtani S; Younossi I; Ahmed A; Racila A; Henry L
Clin Gastroenterol Hepatol; 2021 Mar; 19(3):580-589.e5. PubMed ID: 32531342
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
Tian Z; Xu C; Yang P; Lin Z; Wu W; Zhang W; Ding J; Ding R; Zhang X; Dou K
Front Immunol; 2022; 13():984728. PubMed ID: 36189208
[TBL] [Abstract][Full Text] [Related]
20. Trends and disparities in the utilization of systemic chemotherapy in patients with metastatic hepato-pancreato-biliary cancers.
Elshami M; Ahmed FA; Kakish H; Hue JJ; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
HPB (Oxford); 2023 Feb; 25(2):239-251. PubMed ID: 36411233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
